AAV vectors with high transduction efficiency and uses thereof for gene therapy

1. An AAV VP3 protein comprising:

(a) a non-lysine amino acid residue at a position that corresponds to K258, K490, or K665 of the wild-type AAV2 capsid protein of SEQ ID NO:2, wherein the AAV VP3 protein is an AAV2, AAV3, or AAV6 serotype VP3 protein;

(b) a non-lysine amino acid residue at a position that corresponds to K530 or K547 of the wild-type AAV8 capsid protein of SEQ ID NO:8, wherein the AAV VP3 protein is an AAV1, AAV3, AAV6, AAV7, AAV8, AAV9 or AAV10 serotype VP3 protein;

(c) a non-lysine amino acid residue at a position that corresponds to K569 of the wild-type AAV8 capsid protein of SEQ ID NO: 8, wherein the AAV VP3 protein is an AAV1, AAV6, AAV8, AAV9, or AAV10 serotype VP3 protein;

(d) a non-lysine amino acid residue at a position that corresponds to K258, K490, K507, K527, K532, K549, K556, K665, or K706 of the wild-type AAV2 capsid protein of SEQ ID NO:2, wherein the non-lysine amino acid residue is glutamic acid;

(e) a non-lysine amino acid residue at a position that corresponds to K490, K527, or K544 of the wild-type AAV2 capsid protein of SEQ ID NO:2, wherein the non-lysine amino acid residue is arginine; or

(f) a non-lysine amino acid residue at a position that corresponds to K530 or K569 of the wild-type AAV8 capsid protein of SEQ ID NO:8, wherein the non-lysine amino acid residue is glutamic acid.

2. The AAV VP3 protein, according to claim 1 , comprising a non-lysine amino acid residue at a position that corresponds to K258, K490, or K665 of the wild-type AAV2 capsid protein of SEQ ID NO:2, wherein the AAV VP3 protein is an AAV2, AAV3, or AAV6 serotype VP3 protein.

3. The AAV VP3 protein, according to claim 1 , comprising a non-lysine amino acid residue at a position that corresponds to K530 or K547 of the wild-type AAV8 capsid protein of SEQ ID NO:8, wherein the AAV VP3 protein is an AAV1, AAV3, AAV6, AAV7, AAV8, AAV9 or AAV10 serotype VP3 protein.

4. The AAV VP3 protein, according to claim 1 , comprising non-lysine amino acid residues at positions corresponding to K544 and K556 of the wild-type AAV2 capsid protein of SEQ ID NO:2, wherein the non-lysine amino acid residue at the position corresponding to K556 is glutamic acid, and wherein the AAV VP3 protein is not an AAV5 or AAV6 serotype VP3 protein.

5. The AAV VP3 protein, according to claim 1 , wherein the non-lysine amino acid residue at the position that corresponds to K258, K490, or K665 of the wild-type AAV2 capsid protein of SEQ ID NO:2 or at the position corresponding to K530, K547, or K569 of the wild-type AAV8 capsid protein of SEQ ID NO:8 is selected from glutamic acid (E), arginine (R), serine (S), or isoleucine (I).

6. The AAV VP3 protein, according to claim 1 , comprising a non-lysine amino acid residue at a position that corresponds to K258, K490, K507, K527, K532, K549, K556, K665, or K706 of the wild-type AAV2 capsid protein of SEQ ID NO:2, wherein the non-lysine amino acid residue is glutamic acid, and wherein the AAV VP3 protein is an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or AAV10 serotype VP3 protein.

7. The AAV VP3 protein, according to claim 1 , comprising a non-lysine amino acid residue at the position corresponding to K556 of the wild-type AAV2 capsid protein of SEQ ID NO:2, wherein the non-lysine amino acid residue is a glutamic acid, and further comprising a glutamic acid at a position corresponding to K544 of the wild-type AAV2 capsid protein of SEQ ID NO:2.

8. The AAV VP3 protein, according to claim 1 , comprising a non-lysine amino acid residue at a position that corresponds to K530 or K569 of the wild-type AAV8 capsid protein of SEQ ID NO:8, wherein the non-lysine amino acid residue is glutamic acid, and wherein the AAV VP3 protein is an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or AAV10 serotype VP3 protein.

9. A nucleic acid molecule encoding an AAV VP3 protein according to claim 1 .

10. An AAV vector comprising a capsid comprising an AAV VP3 protein according to claim 1 .

11. A method of transducing cells, comprising introducing into a host cell, a composition comprising an effective amount of an AAV vector according to claim 10 .

12. The method, according to claim 11 , wherein the non-lysine residue is at the position corresponding to K490, K532, K544, or K556 of the wild-type AAV2 VP3 protein of SEQ ID NO:2 or the non-lysine residue is at the position corresponding to K530, K547, or K569 of the wild-type AAV8 capsid protein of SEQ ID NO:8; wherein the non-lysine amino acid residue at the position corresponding to K490 is glutamic acid or arginine, the non-lysine amino acid residue at the position corresponding to K532 or K556 is glutamic acid, and the non-lysine amino acid residue at the position corresponding to K544 is arginine.

13. The method, according to claim 12 , wherein the non-lysine amino acid residue at the position corresponding to K490 or K556 of the wild-type AAV2 capsid protein of SEQ ID NO:2 is glutamic acid, or the non-lysine amino acid residue at the position corresponding to K530, K547, or K569 of the wild-type AAV8 capsid protein of SEQ ID NO:8 is glutamic acid (E), arginine (R), serine (S), or isoleucine (I).

14. The method, according to claim 13 , wherein the non-lysine amino acid residue at the position corresponding to K490 or K556 of the wild-type AAV2 capsid protein of SEQ ID NO:2 or at the position corresponding to K530, K547, or K569 of the wild-type AAV8 capsid protein of SEQ ID NO:8 is glutamic acid (E).

15. The method, according to claim 11 , wherein the host cell is a mammalian cell.

16. The method, according to claim 11 , wherein the host cell is a endothelial, epithelial, vascular, liver, lung, heart, pancreas, intestinal, kidney, muscle, bone, dendritic, cardiac, neural, blood, brain, fibroblast, or cancer cell.

17. The method, according to claim 11 , wherein the host cell is in a subject.

18. A composition comprising (a) an AAV vector comprising a capsid comprising the AAV VP3 protein in accordance with claim 1 , and (b) a pharmaceutically-acceptable buffer, diluent, or vehicle.

19. The composition according to claim 18 , wherein the AAV VP3 protein is a recombinant AAV VP3 protein.

20. The composition of claim 18 , wherein the AAV vector in the composition further comprises a polynucleotide that encodes a therapeutic agent and that is operably linked to a promoter.

21. The AAV VP3 protein according to claim 1 , wherein the AAV VP3 protein is a recombinant AAV VP3 protein.

22. The AAV VP3 protein according to claim 1 , comprising a non-lysine amino acid residue at a position that corresponds to K490, K527, or K544 of the wild-type AAV2 capsid protein of SEQ ID NO:2, wherein the non-lysine amino acid residue is arginine, and wherein the AAV VP3 protein is an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or AAV10 serotype VP3 protein.

23. The AAV vector of claim 10 , further comprising a polynucleotide that encodes a therapeutic agent and that is operably linked to a promoter.

24. The AAV vector of claim 23 , wherein the promoter is one or more of a heterologous promoter, a tissue-specific promoter, a constitutive promoter, and an inducible promoter.

25. The AAV vector of claim 23 , wherein the promoter is selected from the group consisting of cytomegalovirus (CMV) promoters, desmin (DES) promoters, beta-actin promoters, insulin promoters, enolase promoters, BDNF promoters, NGF promoters, EGF promoters, growth factor promoters, axon-specific promoters, dendrite-specific promoters, brain-specific promoters, hippocampal-specific promoters, kidney-specific promoters, elafin promoters, cytokine promoters, interferon promoters, growth factor promoters, alpha-1 antitrypsin promoters, brain-specific promoters, neural cell-specific promoters, central nervous system cell-specific promoters, interleukin promoters, serpin promoters, hybrid CMV promoters, hybrid beta-actin promoters, EF1 promoters, U1a promoters, U1b promoters, Tet-inducible promoters and VP16-LexA promoters.

26. The AAV vector of claim 23 , wherein the therapeutic agent is selected from the group consisting of polypeptides, peptides, antibodies, antigen binding fragments, ribozymes, peptide nucleic acids, siRNA, RNAi, antisense oligonucleotides and antisense polynucleotides.

27. The AAV vector of claim 26 , wherein the therapeutic agent is selected from the group consisting of adrenergic agonists, anti-apoptosis factors, apoptosis inhibitors, cytokine receptors, cytokines, cytotoxins, erythropoietic agents, glutamic acid decarboxylases, glycoproteins, growth factors, growth factor receptors, hormones, hormone receptors, interferons, interleukins, interleukin receptors, kinases, kinase inhibitors, nerve growth factors, netrins, neuroactive peptides, neuroactive peptide receptors, neurogenic factors, neurogenic factor receptors, neuropilins, neurotrophic factors, neurotrophins, neurotrophin receptors, N-methyl-D-aspartate antagonists, plexins, proteases, protease inhibitors, protein decarboxylases, protein kinases, protein kinase inhibitors, proteolytic proteins, proteolytic protein inhibitors, semaphorins, semaphorin receptors, serotonin transport proteins, serotonin uptake inhibitors, serotonin receptors, serpins, serpin receptors, and tumor suppressors.

28. The AAV vector of claim 10 , wherein the AAV VP3 protein comprises a non-lysine amino acid residue at a position that corresponds to K258, K490, K507, K527, K532, K549, K556, K665, or K706 of the wild-type AAV2 capsid protein of SEQ ID NO:2, wherein the non-lysine amino acid residue is a glutamic acid, and wherein the AAV vector is an AAV2 serotype vector.

29. The AAV vector of claim 10 , wherein the AAV VP3 protein comprises a non-lysine amino acid residue at a position that corresponds to K490, K527, or K544 of the wild-type AAV2 capsid protein of SEQ ID NO:2, wherein the non-lysine amino acid residue is arginine, and wherein the AAV vector is an AAV2 serotype vector.

30. The AAV vector of claim 10 , wherein the AAV VP3 protein comprises a non-lysine amino acid residue at a position that corresponds to K530 or K569 of the wild-type AAV8 capsid protein of SEQ ID NO:8, wherein the non-lysine amino acid residue is glutamic acid, and wherein the AAV vector is an AAV8 serotype vector.

31. The AAV VP3 protein according to claim 1 , comprising a non-lysine amino acid residue at a position that corresponds to K569 of the wild-type AAV8 capsid protein of SEQ ID NO: 8, wherein the non-lysine amino acid residue is glutamic acid, and wherein the AAV VP3 protein is an AAV1, AAV6, AAV8, AAV9, or AAV10 serotype VP3 protein.

32. The AAV VP3 protein according to claim 1 , comprising:

(a) a non-lysine amino acid residue at a position that corresponds to K490 of the wild-type AAV2 capsid protein of SEQ ID NO:2, wherein the AAV VP3 protein is an AAV2, AAV3, or AAV6 serotype VP3 protein;

(b) a non-lysine amino acid residue at a position that corresponds to K258, K490, K507, K532, K549, K556, K665, or K706 of the wild-type AAV2 capsid protein of SEQ ID NO:2, wherein the non-lysine amino acid residue is glutamic acid;

(c) a non-lysine amino acid residue at a position that corresponds to K490 of the wild-type AAV2 capsid protein of SEQ ID NO:2, wherein the non-lysine amino acid residue is arginine; or

(d) a non-lysine amino acid residue at a position that corresponds to K530 or K569 of the wild-type AAV8 capsid protein of SEQ ID NO:8, wherein the non-lysine amino acid residue is glutamic acid.